TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Insitro Stock

Insitro Stock

insitro.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $628.63MM

Insitro is a drug discovery and development business using machine learning methods to create predictive models for treatments. Insitro's use of technology and quantitative biology aims to model disease and develop new therapies. Insitro was founded in 2018 by Daphne Koller Ph.D. and is headquartered in San Francisco, CA.

Buy or sell Insitro stockLearn more about Insitro IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Insitro, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Insitro’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Insitro.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Insitro investors also invested in these private companies

Andreessen Horowitz
Arch Venture Partners
Two Sigma Ventures
HOF Capital
Third Rock Ventures
A&E Investments

Team

Management Team

Daphne Koller Ph.D
Co-Founder, Chief Executive Officer & Board Member
Mary Rozenman Ph.D
Chief Financial Officer & Chief Business Officer
Ajamete Kaykas
Chief Technology Officer, Chief Exploration Officer & Head of Neuroscience
Martha Rook
Chief Technical Operations Officer

Board Members

Eli Casdin
Casdin Capital
Krishna Yeshwant MD
GV
Paul McCracken
CPP Investments
Reid Huber Ph.D
Third Rock Ventures
Robert Nelsen
ARCH Venture Partners
Vijay Pande Ph.D
Andreessen Horowitz

Frequently Asked Questions About Insitro’s Stock

plusminus
Can you buy Insitro stock?
Insitro is not publicly traded on NYSE or NASDAQ in the U.S. To buy Insitro stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Insitro stock?
Yes, you can sell stock of a private company like Insitro. Forge can help you sell your Insitro stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Insitro’s stock price?
Insitro is a privately held company and therefore does not have a public stock price. However, you may access Insitro’s private market stock price with Forge Data.
plusminus
What is Insitro’s stock ticker symbol?
Insitro does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Insitro in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Business Wire 12/01/2022
insitro Appoints Philip Tagari, Industry-Leading Scientist and Drug Hunter, as Chief Scientific Officer
Insitro, a machine learning-powered drug discovery and development company, today announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery.
McKinsey 11/16/2022
‘It will be a paradigm shift’: Daphne Koller on machine learning in drug discovery
Her current mission, as the founder and CEO of drug discovery and development company insitro, is to harness the power of machine learning to create better medicines for patients in need.

Trending Companies

Frequently Asked Questions

Updated on: Dec 3, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.